Inocras and the Broad Institute analyzed 8,000+ TCGA cancer genomes to uncover new drivers and create a harmonized dataset ...
PACB stock gains on Lucid Genomics deal, boosting HiFi data analysis and simplifying workflows to speed insights and expand ...
Expands access to streamlined genomic data analysis across the PacBio partner ecosystemMENLO PARK, Calif. & BERLIN, April 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a premier developer of ...
New algorithms support Illumina TruPath™ Genome: v4.5 introdues analytical support for TruPath, leveraging algorithmic advances to resolve 15 highly homologous, medically-relevant genes for rare ...
This study aimed to evaluate the prevalence of pathogenic/likely pathogenic cardiomyopathy variant carriers in a multiancestry US population and examine the risk of adverse clinical outcomes. Among ...
NomosLogic, Inc. today introduced its molecular medicine infrastructure platform, designed to transform raw genomic files into clinically actionable intelligence across pharmacogenomics, disease ...
A wave of AI foundation models built on plant DNA sequences is giving researchers new tools to annotate genomes, predict gene function, and measure crop traits faster than traditional methods allow.
This important study presents a methodologically rigorous framework for stability-guided fine-mapping, extending PICS and generalizing to methods such as SuSiE, supported by comprehensive simulations ...
Introduction: Deficiency of the dihydropyrimidine dehydrogenase enzyme can result in capecitabine-related toxicity due to genetic alterations in the DPYD gene, leading to complete or partial DPD ...
Pharmacogenomics (PGx) is an enabling component of precision medicine, aiming to improve treatment selection and dosing while reducing adverse drug reactions through the use of genetic information in ...
Like islands scattered across a vast intergenic sea, the nearly 20,000 protein-coding genes within the human genome represent a mere 2 percent of its 3 billion base pairs. When, where, and to what ...
Our critic annotates the barbed wordplay of a decision challenging the Trump administration’s theory of executive power. By A.O. Scott A.O. Scott is a critic at large for the Book Review. One of the ...